-
-
This is the final article in a three-part series about the design and conduct of clinical research. The first installment discussed how research begins with the formulation of research questions, and the second reviewed the strengths and limitations of some common study designs. This article will discuss a few key issues in the analysis and interpretation of research findings.
-
Results from this small pilot trial suggest that clinical hypnosis, massage, and energy work can all be offered to people receiving chemotherapy without interfering with conventional medical care. The findings also suggest little clinical benefit, but there are considerable study limitations, and the findings speak more to feasibility than to therapeutic utility.
-
Behavioral therapy works as well as drug treatment for male overactive bladder.
-
On december 6, 2011, the food and drug administra- tion (FDA) announced that "HCG products marketed as weight loss aids are unproven and illegal."
-
Insomnia is relatively common and experienced around the world. Estimates have identified prevalence rates ranging from 5-50%.
-
-
Nutrition is a controversial topic, perhaps because with only minimal effort it is possible to find seemingly credible people advocating for totally opposite messages. In the realm of public media, it is even worse.
Despite public confusion, reviewing the evidence relating nutrition to health and disease yields more clarity than most people realize.
-
The toxicity associated with intestinal habitation by Clostridium difficile ranges from asymptomatic colonization to life-threatening infection. In the United States, C. difficile is the most common cause of health care-associated diarrhea.
-
A low-dose sublingual formulation of Zolpidem has been approved by the FDA for the management of middle-of-the-night (MOTN) awakening. Zolpidem, marketed as Ambien, was originally approved in 1992. The new formulation is marketed by Transcept Pharmaceuticals as Intermezzo.